Specifically, immunofluorescence assays were used to visualize the protein expression and distribution under the four treatments, while the western blot assays were used to examine the protein levels of mTOR, AR, pAR and SMARCD1 in cytoplasmic and nuclear fractions of the EA and AA PCa cells under these treatments. The gene discussed is AR; the disease is posterior cortical atrophy.